|
1
|
Shu SJ, Lei XG, Liang JH, Song YH, Xu Q,
Chen XD, Mao LG and Li ZG: The effects of second messenger cAMP and
its relative components on the contraction of uterine smooth muscle
of rat. Eur Rev Med Pharmacol Sci. 21:1709–1721. 2017.PubMed/NCBI
|
|
2
|
Sakkas LI, Mavropoulos A and Bogdanos DP:
Phosphodiesterase 4 inhibitors in immune-mediated diseases: Mode of
action, clinical applications, current and future perspectives.
Curr Med Chem. 24:3054–3067. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tang HF, Song YH, Chen JC, Chen JQ and
Wang P: Upregulation of phosphodiesterase-4 in the lung of allergic
rats. Am J Respir Crit Care Med. 71:823–828. 2005. View Article : Google Scholar
|
|
4
|
Ma D, Wu P, Egan RW, Billah MM and Wang P:
Phosphodiesterase 4B gene transcription is activated by
lipopolysaccharide and inhibited by interleukin-10 in human
monocytes. Mol Pharmacol. 55:50–57. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang P, Wu P, Ohleth KM, Egan RW and
Billah MM: Phosphodiesterase 4B2 is the predominant
phosphodiesterase species and undergoes differential regulation of
gene expression in human monocytes and neutrophils. Mol Pharmacol.
56:170–174. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jin SL and Conti M: Induction of the
cyclic nucleotide phosphodiesterase PDE4B is essential for
LPS-activated TNF-alpha responses. Proc Natl Acad Sci USA.
99:7628–7633. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Singh SP, Barrett EG, Kalra R,
Razani-Boroujerdi S, Langley RJ, Kurup V, Tesfaigzi Y and Sopori
ML: Prenatal cigarette smoke decreases lung cAMP and increases
airway hyperresponsiveness. Am J Respir Crit Care Med. 168:342–347.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Deng YM, Xie QM, Tang HF, Sun JG, Deng JF,
Chen JQ and Yang SY: Effects of ciclamilast, a new PDE 4 PDE4
inhibitor, on airway hyperresponsiveness, PDE4D expression and
airway inflammation in a murine model of asthma. Eur J Pharmacol.
547:125–135. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tang HF, Chen JQ, Xie QM, Zheng XY, Zhu
YL, Adcock I and Wang X: The role of PDE4 in pulmonary inflammation
and goblet cell hyperplasia in allergic rats. Biochim Biophys Acta
1762. 525–532. 2006.
|
|
10
|
Xie QM, Chen JQ, Shen WH and Bian RL:
Correlative changes of interferon-gamma and interleukin-4 between
cortical layer and pulmonary airway of sensitized rats. Acta
Pharmacol Sin. 23:248–252. 2002.PubMed/NCBI
|
|
11
|
Bian H, Zhang J, Wu P, Varty LA, Jia Y,
Mayhood T, Hey JA and Wang P: Differential type 4 cAMP-specific
phosphodiesterase (PDE4) expression and functional sensitivity to
PDE4 inhibitors among rats, monkeys and humans. Biochem Pharmacol.
68:2229–2236. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Spina D: PDE4 inhibitors: Current status.
Br J Pharmacol. 155:308–315. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jin SL, Goya S, Nakae S, Wang D, Bruss M,
Hou C, Umetsu D and Conti M: Phosphodiesterase 4B is essential for
T(H)2-cell function and development of airway hyperresponsiveness
in allergic asthma. J Allergy Clin Immunol. 126:1252–1259.e12.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Giembycz MA and Newton R: Harnessing the
clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory
lung diseases: Dual-selective phosphodiesterase inhibitors and
novel combination therapies. Handb Exp Pharmacol. 415–446. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Giembycz MA: Can the anti-inflammatory
potential of PDE4 inhibitors be realized: Guarded optimism or
wishful thinking? Br J Pharmacol. 155:288–290. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ashton MJ, Cook DC, Fenton G, Karlsson JA,
Palfreyman MN, Raeburn D, Ratcliffe AJ, Souness JE, Thurairatnam S
and Vicker N: Selective type IV phosphodiesterase inhibitors as
antiasthmatic agents. The syntheses and biological activities of
3-(cyclopentyloxy)-4-methoxybenzamides and analogues. J Med Chem.
37:1696–1703. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Souness JE, Maslen C, Webber S, Foster M,
Raeburn D, Palfreyman MN, Ashton MJ and Karlsson JA: Suppression of
eosinophil function by RP 73401, a potent and selective inhibitor
of cyclic AMP-specific phosphodiesterase: Comparison with rolipram.
Br J Pharmacol. 115:39–46. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cooper N, Teixeira MM, Warneck J, Miotla
JM, Wills RE, Macari DM, Gristwood RW and Hellewell PG: A
comparison of the inhibitory activity of PDE4 inhibitors on
leukocyte PDE4 activity in vitro and eosinophil trafficking in
vivo. Br J Pharmacol. 126:1863–1871. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Favot L, Keravis T and Lugnier C:
Modulation of VEGF-induced endothelial cell cycle protein
expression through cyclic AMP hydrolysis by PDE2 and PDE4. Thromb
Haemost. 92:634–645. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Favot L, Keravis T, Holl V, Le Bec A and
Lugnier C: VEGF-induced HUVEC migration and proliferation are
decreased by PDE2 and PDE4 inhibitors. Thromb Haemost. 90:334–343.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Peter D, Jin SL, Conti M, Hatzelmann A and
Zitt C: Differential expression and function of phosphodiesterase 4
(PDE4) subtypes in human primary CD4+ T cells: Predominant role of
PDE4D. J Immunol. 178:4820–4831. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Beeh KM, Beier J, Lerch C, Schulz AK and
Buhl R: Effects of piclamilast, a selective phosphodiesterase-4
inhibitor, on oxidative burst of sputum cells from mild asthmatics
and stable COPD patients. Lung. 182:369–377. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Aoki M, Kobayashi M, Ishikawa J, Saita Y,
Terai Y, Takayama K, Miyata K and Yamada T: A novel
phosphodiesterase type 4 inhibitor, YM976
(4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one),
with little emetogenic activity. J Pharmacol Exp Ther. 295:255–260.
2000.PubMed/NCBI
|
|
24
|
de Visser YP, Walther FJ, Laghmani EH, van
Wijngaarden S, Nieuwland K and Wagenaar GT: Phosphodiesterase-4
inhibition attenuates pulmonary inflammation in neonatal lung
injury. Eur Respir J. 31:633–644. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
de Visser YP, Walther FJ, Laghmani el H,
Steendijk P, Middeldorp M, van der Laarse A and Wagenaar GT:
Phosphodiesterase 4 inhibition attenuates persistent heart and lung
injury by neonatal hyperoxia in rats. Am J Physiol Lung Cell Mol
Physiol. 302:L56–L67. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Souness JE, Griffin M, Maslen C, Ebsworth
K, Scott LC, Pollock K, Palfreyman MN and Karlsson JA: Evidence
that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha
generation from human monocytes by interacting with a
‘low-affinity’ phosphodiesterase 4 conformer. Br J Pharmacol.
118:649–658. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Raeburn D, Underwood SL, Lewis SA, Woodman
VR, Battram CH, Tomkinson A, Sharma S, Jordan R, Souness JE, Webber
SE and Karlsson JA: Anti-inflammatory and bronchodilator properties
of RP 73401, a novel and selective phosphodiesterase type IV
inhibitor. Br J Pharmacol. 113:1423–1431. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Holbrook M, Gozzard N, James T, Higgs G
and Hughes B: Inhibition of bronchospasm and ozone-induced airway
hyperresponsiveness in the guinea-pig by CDP840, a novel
phosphodiesterase type 4 inhibitor. Br J Pharmacol. 118:1192–1200.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bundschuh DS, Eltze M, Barsig J, Wollin L,
Hatzelmann A and Beume R: In vivo efficacy in airway disease models
of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol
Exp Ther. 297:280–290. 2001.PubMed/NCBI
|
|
30
|
Wollin L, Bundschuh DS, Wohlsen A, Marx D
and Beume R: Inhibition of airway hyperresponsiveness and pulmonary
inflammation by roflumilast and other PDE4 inhibitors. Pulm
Pharmacol Ther. 19:343–352. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sun JG, Deng YM, Wu X, Tang HF, Deng JF,
Chen JQ, Yang SY and Xie QM: Inhibition of phosphodiesterase
activity, airway inflammation and hyperresponsiveness by PDE4
inhibitor and glucocorticoid in a murine model of allergic asthma.
Life Sci. 79:2077–2085. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ji H, Xie QM and Chen JQ: Comparison of
piclamilast with ciclamilast in bronchodilating and antiallergic
effects. Zhejiang Da Xue Xue Bao Yi Xue Ban. 32:274–278. 2003.(In
Chinese). PubMed/NCBI
|
|
33
|
Chen JC, Chen JQ, Xie QM and Zhu YL:
Selective inhibition of purified human phosphodiesterase 4A
expressed in yeast cell GL62 by ciclamilast, piclamilast, and
rolipram. Acta Pharmacol Sin. 25:1171–1175. 2004.PubMed/NCBI
|
|
34
|
Thompson WJ, Ashikaga T, Kelly JJ, Liu L,
Zhu B, Vemavarapu L and Strada SJ: Regulation of cyclic AMP in rat
pulmonary microvascular endothelial cells by rolipram-sensitive
cyclic AMP phosphodiesterase (PDE4). Biochem Pharmacol. 63:797–807.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ahlstrom M, Pekkinen M, Huttunen M and
Lamberg-Allardt C: Dexamethasone down-regulates
cAMP-phosphodiesterase in human osteosarcoma cells. Biochem
Pharmacol. 69:267–275. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Barnes PJ and Adcock IM: Glucocorticoid
resistance in inflammatory diseases. Lancet. 373:1905–1917. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Milara J, Navarro A, Almudever P, Lluch J,
Morcillo EJ and Cortijo J: Oxidative stress-induced glucocorticoid
resistance is prevented by dual PDE3/PDE4 inhibition in human
alveolar macrophages. Clin Exp Allergy. 41:535–546. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tiwari S, Dong H, Kim EJ, Weintraub L,
Epstein PM and Lerner A: Type 4 cAMP phosphodiesterase (PDE4)
inhibitors augment glucocorticoid-mediated apoptosis in B cell
chronic lymphocytic leukemia (B-CLL) in the absence of exogenous
adenylyl cyclase stimulation. Biochem Pharmacol. 69:473–483. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dong H, Zitt C, Auriga C, Hatzelmann A and
Epstein PM: Inhibition of PDE3, PDE4 and PDE7 potentiates
glucocorticoid-induced apoptosis and overcomes glucocorticoid
resistance in CEM T leukemic cells. Biochem Pharmacol. 79:321–329.
2010. View Article : Google Scholar : PubMed/NCBI
|
